openPR Logo
Press release

Global Oncolytic Virus Therapy Market and Pipeline Outlook 2022

06-28-2017 01:16 PM CET | Health & Medicine

Press release from: Kuick Resarch

Global Oncolytic Virus Therapy Market and Pipeline Outlook 2022

“Global Oncolytic Virus Therapy Market and Pipeline Outlook 2022” report analyzes ongoing clinical and non-clinical trends in the oncolytic virus therapy market. Currently there are 2 oncolytic virus therapies commercially available in the market. This report analyzes the ongoing clinical trial of 48 oncolytic virus therapies in clinical pipeline and gives comprehensive clinical insight on various parameters associated with the development of the oncolytic virus therapies. Most of the oncolytic virus therapy in clinical trials are in preclinical phase followed by Phase-I trials
.
The preceding decades have shown the higher incidence and prevalence trends for the cancer. Globally, the scenario is worsening with the mounting number of cancer patients every year. Thousands of regimens have been employed for the eradication of this deadly disease and yet the new interventions are anticipated. Undeniably, several modalities have resulted in some form of relief so far, but the triumph towards cancer abolition is long way road.

Download Report:

https://www.kuickresearch.com/report--global-oncolytic-virus-therapy-market-and-pipeline-outlook-2022.php

The conventional chemotherapy and radiotherapy have limited therapeutic index and a plethora of treatment associated negative effects. The current scenario of the oncological treatment represents the impetus search for the novel therapeutic modalities that can selectively disrupt the tumor cells and block the cancer growth along with the safety, that the treatment will be harmless towards the normal cells.

The major role of developing the new therapy for the treatment of cancer is to have broader therapeutic index which represents the high potency towards the malignant cells with low or no toxicities towards healthy cells. One such approach is the use of the viruses for the treatment of cancer turning into term known as viral oncotherapy. With the advances in oncology and the virology, the routes towards the engineering of viruses with increased tumor selectivity and enhanced oncolytic activity is conceivable.

Therefore the oncolytic virus is a virus that preferentially infects and kills cancer cells, as the infected cancer cells are destroyed by oncolysis, they release new infectious viral particles to help destroy the remaining tumor. Oncolytic viruses perform the dual functions they not only cause the destruction of cancerous cell but also stimulate the host anti-tumor immune responses and don’t allow the growth of tumor cells. Certainly, targeted therapy of cancer using viruses has generated interest in the light of limited efficacy of the standard cancer therapeutics.

The next few years will see progress in terms of viral delivery, in particular the use of immune cell carriers that have yet to enter clinical trials. The promising strategy of combining existing antitumor adoptive cellular therapy with oncolytic viral delivery is likely to be explored. Combinations of viral therapy with chemotherapy, radiotherapy, transient immunosuppression and other immunotherapy strategies will probably be tested in early phase clinical trials.

For the broader future of oncolytic immunotherapy, it is expected that a rapid expansion of the number of clinical trials already being conducted combining this with immune co-inhibitory pathway blockade, improved oncolytic agents being developed (i.e. with greater direct antitumor effects and with an improved ability to spread through tumors), and in particular the ability of viruses to deliver proteins directly to the tumor microenvironment to help further induce, enhance, and shape the anti-tumor immune response being exploited to a greater extent.

For Report Sample Contact: neeraj@kuickresearch.com or

visit: https://www.kuickresearch.com

Recent Publications:

* Global Cancer Immunotherapy Market & Clinical Trials Outlook 2022
* Global CAR T Cell Therapy Market & Clinical Trials Insight 2022
* Global Dendritic Cell Cancer Vaccine Market & Clinical Trials Outlook 2023
* Global Microcapsules Drug Delivery Market Opportunity Outlook 2022
* Global Controlled Drug Delivery Market & Clinical Trial Outlook 2022
* Global Cancer Antibody Drug Conjugates Market & Pipeline Insight 2022
* Global B Cell Lymphoma Market & Clinical Pipeline Insight 2022

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Oncolytic Virus Therapy Market and Pipeline Outlook 2022 here

News-ID: 600142 • Views:

More Releases from Kuick Resarch

Lumakras Drug Clinical Insight and Sales Forecast 2026
Lumakras Drug Clinical Insight and Sales Forecast 2026
"Lumakras Drug Clinical Insight and Sales Forecast 2026" Report Highlights: * NSCLC Targeting Lumakras Market Opportunity (US$ Million) * Colorectal Cancer Targeting Lumakras Market Opportunity (US$ Million) * Pharmacokinetics of Lumakras (Sotorasib) * Dosage, Patent and Price Analysis * Lumakras Ongoing Clinical Trials * Global KRAS Protein Inhibitors Clinical Trials Download Report: https://www.kuickresearch.com/report-lumakras-sotorasib-sales-forecast-fda-approved-kras-inhibitor-clinical-trials-non-small-cell-lung-cancer-nslc-g12c-mutation-c30h30f2n6o3-ras-gtpase The rising burden of cancer and the increasing cancer mortality rates possesses an unmet need for the development of novel therapies in the management
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
"Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026" Report Highlights: * Global EZH2 Inhibitor Market Opportunity > US$ 1.2 Billion by 2026 * Tazverik (Tazemetostat) First Approved EZH2 Inhibitor Drug * Dosage, Price and Sales Analysis of Tazverik * Tazverik Sales Opportunity > US$ 900 Million by 2026 * Tazverik Sales Forecast 2021 Till 2026 * EZH2 Inhibitor Clinical Pipeline Overview By Company, Indication and Phase * EZH2 Inhibitor in Clinical Trials: 7 Drugs Download
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Tr …
"Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028" Report Highlights: * Global Bispecific Antibody Market Opportunity: > US$ 20 Billion * Global Bispecific Antibody Market Growth Rate: 100% CAGR (2016 -2021) * Approved Bispecific Antibodies In Market: 4 Antibodies * Detailed Market Sales and Trends Insight Till 2028 * Quarterly and Yearly Sales Insight Of Approved Antibodies Till Q1 2022 * Global and Regional Market Analysis * Approved Drug Sales
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and C …
"Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026" Report Highlights: * Global FGFR Inhibitors Market Opportunity: > USD 4 Billion by 2026 * Role of FGFR Inhibitors in Cancer Therapy * Global FGFR Market Assessment (US$) by Region and Cancer Type Clinical and Sales Insight on Approved FGFR Inhibitors: 3 (Belvesra, Pemazyre and Truseltiq) * Dosage and Drug Price Insight on Approved FGFR Inhibitors * Comprehensive Clinical Trials Insight

All 5 Releases


More Releases for Pipeline

Refined Petroleum Products Pipeline Transportation Global Market 2018: Key Playe …
Refined petroleum products pipeline transportation industry comprises establishments primarily engaged in the pipeline transportation of refined petroleum products. Introduction of new and advanced technologies in the industry is highly increasing the demand of refined petroleum products pipeline transportation market. Several countries has begun with the usage of drones and advanced surveillance systems for pipeline monitoringand also to protect oil pipelines from any disrupt acts. With these new robotics and IoT solutions
Pipeline of Batten Disease Market Pipeline Review, H2 2017
"The Report Batten Disease - Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Batten Disease - Pipeline Review, H2 2017, provides an overview of the Batten Disease (Central Nervous System) pipeline landscape. Batten disease, a rare genetic disorder, belongs to a group of progressive degenerative neurometabolic disorders known
Pressure Ulcers (Dermatology) Pipeline Landscape H2, 2017 - Pharmaceutical Pipel …
Market Research Hub's latest Pharmaceutical and Healthcare disease pipeline guide Pressure Ulcers Pipeline Review, H2 2017, provides an overview of the Pressure Ulcers (Dermatology) pipeline landscape. Pressure ulcers are an injury that breaks down the skin and underlying tissue. The parts of the body most at risk of developing pressure ulcers are those that are not covered by a large amount of body fat and are in direct contact with
Hypotension (Cardiovascular) Pipeline Review H2, 2017 - Pharmaceutical Pipeline …
Market Research Hub's latest Pharmaceutical and Healthcare disease pipeline guide Hypotension Pipeline Review, H2 2017, provides an overview of the Hypotension (Cardiovascular) pipeline landscape. Low blood pressure, or hypotension, occurs when blood pressure during and after each heartbeat is much lower than usual. This means the heart, brain, and other parts of the body do not get enough blood. Symptoms include blurred vision, dizziness, confusion, sleeplessness, and weakness. Treatment is
Hypotension (Cardiovascular) Pipeline Review H2, 2017 - Pharmaceutical Pipeline …
Market Research Hub's latest Pharmaceutical and Healthcare disease pipeline guide Hypotension Pipeline Review, H2 2017, provides an overview of the Hypotension (Cardiovascular) pipeline landscape. Low blood pressure, or hypotension, occurs when blood pressure during and after each heartbeat is much lower than usual. This means the heart, brain, and other parts of the body do not get enough blood. Symptoms include blurred vision, dizziness, confusion, sleeplessness and weakness. Treatment is
Cluster Headache Syndrome Pipeline Review H2, 2017 - Pharmaceutical Pipeline Gui …
Market Research Hub's latest Pharmaceutical and Healthcare disease pipeline guide Cluster Headache Syndrome Pipeline Review, H2 2017, provides an overview of the Cluster Headache Syndrome pipeline landscape. Cluster headache is pain that occurs along one side of the head. It is frequently occurs around, behind, or above the eye. Symptoms include burning, sharp, steady pain, red eye, runny nose, excessive tearing and flushed face. Risk factors include age and gender.